Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

BioNTech SE

Pfizer

What Pfizer, BioNTech, and Moderna Are Doing to Fight the Deadly Delta Variant

Curaleaf Holdings, Inc.

Danaher

GlaxoSmithKline

IQVIA Hlds

Intuitive Surgical

Jazz Pharmaceuticals

LHC Group

Invesco S&P 500 Equal Weight Health Care ETF

UnitedHealth Group

Vertex Pharmaceuticals

The 2020s could be the decade of healthcare stocks. Here are 10 companies and one ETF to watch not just for the remainder of this year, but well beyond.

11 Best Healthcare Stocks for the Rest of 2021

The COVID-19 vaccine maker has been well rewarded for coming up with a stopgap solution as quickly as it did.

Here's Why Moderna Stock Soared 125% During the First 6 Months of 2021

Moderna (MRNA) signs an agreement with the government of Argentina for supplying 20 million doses of its COVID-19 vaccine, mRNA-1273, or an updated booster vaccine shot, if approved.

Moderna (MRNA) Set to Supply Argentina With COVID-19 Vaccine

They've vaccinated the largest percentage of Americans against the coronavirus.

The Best Stock for the Second Half: Moderna or BioNTech?

Johnson & Johnson

"The data are about as good as it gets," Dr. Anthony Fauci told CNBC, saying he expects Pfizer, Moderna and J&J's vaccines to receive full FDA approval.

Fauci says he would be 'astounded' if Pfizer, Moderna and J&J Covid vaccines don't get full FDA approval

Boosters could add billions to revenue in the long term.

Pfizer vs. Moderna: Which Company's Booster Will Dominate?

There's a bit of a brouhaha over booster doses.

Why the CDC and FDA Just Slapped Down Pfizer and Moderna

AstraZeneca

Novavax

Based on company forecasts, Wall Street estimates, and author guestimates, the top coronavirus vaccine developers will bring in billions of dollars in sales this year.

COVID-19 Vaccines: How Much Revenue Will Each Drugmaker Generate in 2021?

Moderna Inc. (NASDAQ:MRNA) shares were trading higher Monday, likely after the company announced a supply agreement with Argentina for 20 million doses of its COVID-19 vaccine. The company said if authorized, it would begin delivery in the first quarter of 2022.

Moderna Stock Looks To Have Broken Out: What Comes Next?

In a few days, Moderna Inc (NASDAQ: MRNA) will start a trial designed to evaluate pregnancy outcomes in women after receiving the Company's COVID-19 shot during their pregnancy. According to an update posted on the ClinicalTrials.gov website, the trial will begin on July 22, targeting the enrollment of 1,000 participants.

Moderna Outlines Pregnancy Outcome Study Details For Its COVID-19 Shot

Shares of Moderna Inc. were up 0.9% in trading on Monday after the company said it will supply 20 million doses of its COVID-19 vaccine to Argentina. The order may include COVID-19 booster shots, if those doses are eventually authorized.

Moderna to supply 20 million doses of its COVID-19 vaccine to Argentina

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces supply agreement with Argentina for 20 million doses of its COVID-19 vaccine.

Moderna Announces Supply Agreement with Argentina for 20 Million Doses of its COVID-19 Vaccine

It has to do with the companies' next step in the coronavirus vaccine rollout.

Does This Shocking CDC Statement Mean Trouble for Pfizer and Moderna?

They're about streamlining your annual vaccine routine.

19 Words from Moderna's CEO That May Guarantee Billions in Revenue for the Long Term

There's good news and bad news for investors.

How Is Moderna's COVID Vaccine Holding Up Against Variants?

Beyond Meat

Delta Air Lines

NIKE

Wells Fargo

Q.ai runs daily factor models to get the most up-to-date reading on stocks and ETFs. Today, our deep-learning algorithms have identified Beyond Meat, Inc among others.

Beyond Meat, Inc Ranked Among Today's Trending Stocks

These are Insider's biggest healthcare stories for the week ending July 9.

We visited Moderna's labs - Amazon's healthcare push - Who owns medical practices

Maybe, but it's still too soon to know for sure.

Could Pfizer and Moderna Be in Trouble After the Latest COVID Vaccine Findings?

Moderna (MRNA) doses the first participant in a phase I/II study on its quadrivalent mRNA-based vaccine candidate, mRNA-1010, against seasonal influenza.

Moderna (MRNA) Begins Dosing in Study on mRNA Flu Vaccine

COVID-19 concerns are driving the vaccine stocks higher.

Why Moderna and Novavax Stocks Are Jumping Today

Per the latest CDC data, the Delta variant now makes up almost half of the COVID-19 cases in the United States.

Vaccine Stocks Fall as Delta Becomes Dominant Variant in US

Inovio Pharmaceuticals

Ocugen, Inc.

Stock markets moved slightly higher despite general worries.

With COVID-19 Variant Threats Rising, Why Are Vaccine Stocks Falling?

Moderna Inc (NASDAQ: MRNA) has initiated a Phase 1/2 study and dosed the first patient with mRNA1010, its quadrivalent vaccine for seasonal flu. The candidate is designed to target lineup lineages that include influenza A H1N1, H3N2, and influenza B Yamagata and Victoria.

Moderna Puts Its First Seasonal Flu Vaccine In The Clinic

Moderna is aiming to employ the technology used to make its Covid-19 shot to produce a more effective flu vaccine.

News for Moderna Stock (MRNA)